Development of chaperonin 10-based second generation biopharmaceuticals for treatment of inflammatory diseases (2010-2013)
Abstract
The project seeks to develop second generation biopharmaceuticals based on chaperonin 10 (Cpn10), which has been shown to be efficaceous in Phase IIa clinical trials for both rheumatoid arthritis and psoriasis. A series of mutants will be produced based on recent structure determination of Cpn10 and known sequence motifs, and tested in animal models of inflammatory disease including a rat collagen-induced arthritis and inflammatory bowel disease models. The development of second generation, Cpn10-based biopharmaceuticals will have applicatons over a wide variety of inflammatory diseases and will establish Cpn10 and Cpn10-based entities as a new class of anti-inflammatory agents. '',
